metastatic hormone refractory prostate cancer global api manufacturers marketed and phase iii drugs landscape

"Metastatic Hormone Refractory Prostate Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2025" report by DelveInsight offers comprehensive insights on marketed and Phase III products for Metastatic Hormone Refractory Prostate Cancer. The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2028. It further provides the marketed products API manufacturer details for United States, Europe, China, and India. The report also covers the emerging Phase III pipeline assets for Metastatic Hormone Refractory Prostate Cancer including their detailed product profiles.

Additionally, the report also highlights the future competitive landscape for Metastatic Hormone Refractory Prostate Cancer therapeutics. Depending on information availability comprehensive coverage of the following for Metastatic Hormone Refractory Prostate Cancer marketed products for Metastatic Hormone Refractory Prostate Cancer descriptive marketed product profiles for Metastatic Hormone Refractory Prostate Cancer including (but not limited to) drug description, regulatory milestones, product development and R&D activities encompassing clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are the historical and forecasted global sales till 2028 for each product.

Global API Manufacturers of marketed products for Metastatic Hormone Refractory Prostate Cancer coverage of API manufacturers for Metastatic Hormone Refractory Prostate Cancer marketed products spanning across United States, Europe, China and India. The manufacturers details include manufacturers name along with their location Emerging Phase III products for Metastatic Hormone Refractory Prostate Cancer descriptive Phase III product profiles for Metastatic Hormone Refractory Prostate Cancer including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also their forecasted global sales are provided till 2028.

Report Methodology 

The report provides insights into: 

• Detailed description of the indication including causes, symptoms, pathophysiology, diagnosis and treatment
• Comparative analysis of the marketed and emerging products 
• Detailed profiles for the marketed therapies available including mechanism of action, dosage and administration regulatory milestones, other development activities 
• Global sales of the marketed therapies from 2020-2028 is covered in the report
• Global API Manufacturers for marketed therapies are provided across United States, Europe, China and India
• List of emerging therapies with product name, company, stage of development, indication, route of administration and molecule type is also provided  

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.

Metastatic Hormone Refractory Prostate Cancer Recent Developments

• In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
• In September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
• In July 2024, the ARANOTE trial showed that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
• In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
• In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.
• In May 2024, Fusion Pharmaceuticals began the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.
• In April 2024, Astellas Pharma received European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
• In April 2024, FibroGen announced positive Phase 1 trial data for FG-3246 in mCRPC.
• On November 16, 2023, the FDA approved enzalutamide (Xtandi) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence.

Metastatic Hormone Refractory Prostate Cancer Analytical Perspective by DelveInsight

• In-depth Metastatic Hormone Refractory Prostate Cancer Commercial Assessment of Marketed Products 

This report provides an in-depth commercial assessment of marketed products, which comprises the details of collaborations, licensing, acquisition - deal value trends, patent and global sales.

• Metastatic Hormone Refractory Prostate Cancer Clinical Assessment of Emerging Products

The report comprises of comparative clinical assessment of products by development stage, route of administration and molecule type across this indication.

Scope of the report

• The Metastatic Hormone Refractory Prostate Cancer report provides a comprehensive understanding of Metastatic Hormone Refractory Prostate Cancer marketed and emerging (Phase III) products
• Access to API manufacturers details for Metastatic Hormone Refractory Prostate Cancer marketed drugs to devise API procurement strategy for generic development
• Plan developmental timelines around marketed drug patents for the major markets- US and EU
• Understand current and future growth of marketed Metastatic Hormone Refractory Prostate Cancer therapeutics through their historical and forecasted sales
• Identify and analyze future sales trends of emerging Phase III Metastatic Hormone Refractory Prostate Cancer therapeutics through their forecasted sales
• Identify the products attributes and use it for target finding, drug repurposing, and precision medicine
• Identify and plan ahead for prospective emerging players and their products for Metastatic Hormone Refractory Prostate Cancer

Report highlights

• In the coming years, the Metastatic Hormone Refractory Prostate Cancer market is set to change due to the extensive research in this filed, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Hormone Refractory Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• There are many companies involved in developing therapies for Metastatic Hormone Refractory Prostate Cancer. Launch of emerging therapies of Metastatic Hormone Refractory Prostate Cancer will significantly impact the market.
• A better understanding of target mechanism will also contribute to the development of novel therapeutics for Metastatic Hormone Refractory Prostate Cancer.
• Our in-depth analysis of the marketed and late-stage pipeline assets comparative analysis of the products. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

• What are the current treatment options available based on the Metastatic Hormone Refractory Prostate Cancer?
• How many companies are developing therapies for Metastatic Hormone Refractory Prostate Cancer?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for Metastatic Hormone Refractory Prostate Cancer to treat disease condition?
• How many emerging therapies are in late stage of development for Metastatic Hormone Refractory Prostate Cancer?
• What is the trend of historical and forecasted sales of the marketed products from the period 2020-2028?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Metastatic Hormone Refractory Prostate Cancer therapies? 
• Which are the API manufacturers across United States, Europe, China and India for the marketed therapies?
• How many patents are granted to the marketed therapies of Metastatic Hormone Refractory Prostate Cancer?
• How late-stage emerging therapies are distinguished on the basis of their mechanism of action, route of administration and molecule type?